Our Annual Report provides a wide range of information about our global business and how we are working, both within the company and in partnership with others, to meet complex healthcare challenges and deliver life-changing medicines for people worldwide.
Latest Stock Exchange announcements
Fasenra (benralizumab) receives US FDA approval for severe eosinophilic asthma
Benralizumab receives positive EU CHMP opinion for severe, uncontrolled eosinophilic asthma
Year-To-Date and Q3 2017 Results
Transparency Directive Voting Rights and Capital
AstraZeneca and Aspen complete agreement for residual rights to anaesthetic medicines
Our Annual Report provides a wide range of information about our global business.
Answers to frequently asked shareholder questions.
Our pipeline forms a robust portfolio of investigational therapies in varied stages of clinical development